Skip to main content
genOway logo

genOway — Investor Relations & Filings

Ticker · ALGEN ISIN · FR0004053510 LEI · 969500HMHUPR3KYXUT19 PA Professional, scientific and technical activities
Open in API
Filings indexed 74 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country FR France
Listing PA ALGEN

About genOway

https://www.genoway.com

genOway is a biotechnology company that specializes in designing and developing genetically modified preclinical models. It provides biopharmaceutical companies and academic researchers with genetically engineered mouse, rat, and cell line models intended to improve the predictability of preclinical research. The company's portfolio includes a catalog of off-the-shelf models as well as customized model creation services. Key areas of application for its models include immuno-oncology and pharmacokinetic (PK) analysis, featuring a range of humanized models. genOway emphasizes a collaborative approach, providing scientifically validated solutions to support the development of new therapies for clinical trials.

Recent filings

Filing Released Lang Actions
Poursuite du développement international : lancement d'un modèle de ' Franchises genOway ' avec l'ouverture des deux premières au Canada et en Australie
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the signing of two franchise distribution agreements (Canada and Australia) and outlining the company’s international development strategy. There is no mention of formal financial results, management changes, dividends, capital raising, or filing of a formal report. It is thus a general regulatory announcement that does not fit any other specific category, making it a fallback Regulatory Filing (RNS).
2026-04-14 French
Solides résultats annuels 2025 avec une marge d'EBITDA de 21% en progression - Confirmation de l'objectif d'une croissance organique à deux chiffres sur l'exercice 2026
Earnings Release Classification · 85% confidence The document is a press release providing the audited full‐year financial statements for the fiscal year ended December 31, 2025, including income statement, balance sheet, net debt schedule, narrative commentary, and outlook. It represents the initial announcement of the company’s annual financial results rather than a governance filing, insider transaction, or simple notice of publication. This aligns with an Earnings Release (ER), which covers key highlights and detailed results for a reporting period. FY 2025
2026-03-30 French
genOway poursuit son développement international : création de sa filiale genOway Japan pour pénétrer plus efficacement le 3ème marché mondial de la recherche préclinique et viser 5 à 10 M EUR de reve
Board/Management Information Classification · 85% confidence The document is a press release announcing the creation of a new subsidiary (genOway Japan) and the appointment of a new general manager (Dr. Hideki Hanaoka) and board chair (Philippe Fauchet). It focuses on corporate management changes rather than financial results, legal proceedings, or voting matters. Therefore, it falls under Board/Management Information (MANG).
2026-03-25 French
Succès de la nouvelle organisation commerciale avec un 2nd semestre stable - Chiffre d'affaires annuel de 21 M EUR - Bonne visibilité sur le 1er semestre 2026 - Croissance organique supérieure à +10%
Earnings Release Classification · 95% confidence The document is a comprehensive press release from genOway detailing its annual financial results for the fiscal year 2025, including revenue figures, strategic updates (ROUTE50*DATA), and management changes. While it contains management commentary and a board/management announcement, the primary purpose and the bulk of the content focus on the initial announcement of financial results (Earnings Release). It does not meet the criteria for a full 10-K or Interim Report as it is a summary press release. FY 2025
2026-01-26 French
Bilan semestriel du contrat de liquidité au 31 décembre 2025
Transaction in Own Shares Classification · 100% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Half-year report on the liquidity contract) for genOway, covering the period ending December 31, 2025. It details the number of shares and cash held in the liquidity account and provides a comprehensive table of transactions (purchases and sales) conducted during the second half of 2025. This type of disclosure is a standard regulatory requirement for companies listed on Euronext to report on share buyback/liquidity programs. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct category for reports detailing company buybacks or liquidity contract activity.
2026-01-19 French
Publication du chiffre d'affaires annuel 2025 : lundi 26 janvier 2026 (après Bourse) - Organisation d'un webinaire destiné aux investisseurs individuels
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3628 characters) informing investors about the upcoming publication date of the 2025 annual revenue and the scheduling of an investor webinar. It does not contain the actual financial results, but rather serves as a notification of the event. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-01-19 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.